MDSpire - Takeaway
From the Journals

Fluvoxamine Reduces Long COVID Fatigue in Trial

A randomized, placebo-controlled trial found the selective serotonin reuptake inhibitor improved fatigue severity vs placebo, while metformin showed no evidence of benefit.

Share

  • 1

    REVIVE-TOGETHER trial involved 399 patients with long COVID.

  • 2

    Fluvoxamine reduced fatigue severity effectively compared to placebo.

  • 3

    Metformin showed no significant improvement in fatigue.

  • 4

    Patients were enrolled across Brazil from October 2023 to February

  • 5

    Fluvoxamine improved health-related quality of life at multiple follow-ups.

  • 6

    Adverse events were lower with fluvoxamine than placebo and metformin.

  • 7

    Further trials are recommended to explore fluvoxamine's benefits.

Original Source(s)

Fluvoxamine Reduces Long COVID Fatigue in Trial

  • by Kerri Miller

  • April 2, 2026

Related Content

Inside Access, Outside the Rules

Two federal cases highlight alleged misuse of professional roles in health care settings

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.

Tirzepatide Linked to Greater QoL Gains vs Dulaglutide

Both groups improved, with numerically larger gains in patient-reported outcomes following a switch to tirzepatide